Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 1;387(22):2092-2094.
doi: 10.1056/NEJMc2211283. Epub 2022 Nov 9.

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose

Michal Canetti  1 , Noam Barda  1 , Mayan Gilboa  1 , Victoria Indenbaum  2 , Keren Asraf  1 , Tal Gonen  1 , Yael Weiss-Ottolenghi  1 , Sharon Amit  1 , Ram Doolman  1 , Ella Mendelson  2 , Laurence S Freedman  1 , Yitshak Kreiss  1 , Yaniv Lustig  2 , Gili Regev-Yochay  3
Affiliations

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose

Michal Canetti et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Six-Month Follow-up of Immunogenicity and Vaccine Effectiveness after a Fourth BNT162b2 Vaccine Dose.
Panels A and B show IgG and neutralizing antibody titers, respectively, up to 26 weeks after the second, third, and fourth doses of the BNT162b2 (Pfizer–BioNTech) vaccine. Locally weighted scatterplot smoothing is overlaid. Panel C shows the vaccine effectiveness against any severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 7 to 35 days, 36 to 102 days, 103 to 181 days, and 7 to 181 days (representing the full study period [darker-shaded area]) after the fourth vaccine dose (administered at least 4 months after receipt of the third dose) as compared with the effectiveness of three vaccine doses. Vaccine effectiveness (measured as 1 minus the hazard ratio) is estimated from a Cox proportional hazards regression model, with adjustment for age, sex, and professional role. Calendar time was used as the time scale to further adjust for differing infection prevalence over time. A dashed horizontal line is shown at a hazard ratio of 1, which indicates no effect. 𝙸 bars indicate 95% confidence intervals. BAU denotes binding antibody units.
See this image and copyright information in PMC

References

    1. Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med 2021;385(24):e84-e84. - PMC - PubMed
    1. Kliker L, Zuckerman N, Atari N, et al. COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 omicron variants, Israel, March to June 2022. Euro Surveill 2022;27:2200559-2200559. - PMC - PubMed
    1. Barda N, Dagan N, Cohen C, et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 2021;398:2093-2100. - PMC - PubMed
    1. Magen O, Waxman JG, Makov-Assif M, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 2022;386:1603-1614. - PMC - PubMed
    1. Bar-On YM, Goldberg Y, Mandel M, et al. Protection by a fourth dose of BNT162b2 against omicron in Israel. N Engl J Med 2022;386:1712-1720. - PMC - PubMed